KR102266889B1 - 복막 치료액 - Google Patents

복막 치료액 Download PDF

Info

Publication number
KR102266889B1
KR102266889B1 KR1020197006327A KR20197006327A KR102266889B1 KR 102266889 B1 KR102266889 B1 KR 102266889B1 KR 1020197006327 A KR1020197006327 A KR 1020197006327A KR 20197006327 A KR20197006327 A KR 20197006327A KR 102266889 B1 KR102266889 B1 KR 102266889B1
Authority
KR
South Korea
Prior art keywords
peritoneal
treatment
bca
solution
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197006327A
Other languages
English (en)
Korean (ko)
Other versions
KR20190025759A (ko
Inventor
구이도 그렌트츠맨
Original Assignee
옵테리온 헬스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옵테리온 헬스 아게 filed Critical 옵테리온 헬스 아게
Publication of KR20190025759A publication Critical patent/KR20190025759A/ko
Application granted granted Critical
Publication of KR102266889B1 publication Critical patent/KR102266889B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
KR1020197006327A 2015-07-20 2016-07-19 복막 치료액 Active KR102266889B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
EP15177544.2 2015-07-20
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid
KR1020187001830A KR20180048577A (ko) 2015-07-20 2016-07-19 복막 치료액

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187001830A Division KR20180048577A (ko) 2015-07-20 2016-07-19 복막 치료액

Publications (2)

Publication Number Publication Date
KR20190025759A KR20190025759A (ko) 2019-03-11
KR102266889B1 true KR102266889B1 (ko) 2021-06-18

Family

ID=53785450

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197006327A Active KR102266889B1 (ko) 2015-07-20 2016-07-19 복막 치료액
KR1020187001830A Ceased KR20180048577A (ko) 2015-07-20 2016-07-19 복막 치료액

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187001830A Ceased KR20180048577A (ko) 2015-07-20 2016-07-19 복막 치료액

Country Status (23)

Country Link
US (2) US20180221303A1 (enExample)
EP (2) EP3120842A1 (enExample)
JP (1) JP6448847B2 (enExample)
KR (2) KR102266889B1 (enExample)
CN (2) CN110075307A (enExample)
AU (1) AU2016296216B2 (enExample)
BR (1) BR112018001005B1 (enExample)
CA (1) CA2990532C (enExample)
CO (1) CO2018000236A2 (enExample)
CY (1) CY1124467T1 (enExample)
DK (1) DK3324951T3 (enExample)
ES (1) ES2880796T3 (enExample)
HR (1) HRP20211319T1 (enExample)
HU (1) HUE055208T2 (enExample)
LT (1) LT3324951T (enExample)
MX (1) MX387020B (enExample)
PL (1) PL3324951T3 (enExample)
PT (1) PT3324951T (enExample)
RS (1) RS62142B1 (enExample)
RU (1) RU2718908C2 (enExample)
SI (1) SI3324951T1 (enExample)
SM (1) SMT202100428T1 (enExample)
WO (1) WO2017013120A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
WO2020081654A1 (en) * 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
IL147500A0 (en) * 1999-08-10 2002-08-14 Ml Lab Plc Method for delivery of therapeutic agents using a solution of dextrin
AU7879500A (en) 1999-10-15 2001-04-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
CN101296693B (zh) 2005-10-26 2012-07-04 花王株式会社 持久力提高剂
ES2685094T3 (es) * 2007-07-31 2018-10-05 Elc Management Llc Composiciones cosméticas que contienen resveratrol
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
KR20110096132A (ko) * 2008-11-26 2011-08-29 리포프로틴 테크놀로지스, 인코포레이티드 레스베라트롤의 향상된 생활성 제제
EP3085365A3 (en) * 2009-01-19 2017-01-04 Lycored Ltd. Synergistic combinations of carotenoids and polyphenols
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
PE20150288A1 (es) * 2012-04-24 2015-02-22 Univ British Columbia Dialisato a base de polimero
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
ITRM20130135A1 (it) * 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemico-Biological Interactions,, vol.195, pp.95-104 (2011.11.15.)*

Also Published As

Publication number Publication date
BR112018001005A2 (pt) 2022-09-06
CY1124467T1 (el) 2022-07-22
RU2018106122A3 (enExample) 2019-10-10
US11160766B2 (en) 2021-11-02
BR112018001005B1 (pt) 2023-11-28
ES2880796T3 (es) 2021-11-25
PL3324951T3 (pl) 2021-12-13
HUE055208T2 (hu) 2021-11-29
MX2018000336A (es) 2018-05-22
MX387020B (es) 2025-03-19
SMT202100428T1 (it) 2021-09-14
US20180221303A1 (en) 2018-08-09
EP3324951B1 (en) 2021-05-26
PT3324951T (pt) 2021-07-20
CN107921009A (zh) 2018-04-17
LT3324951T (lt) 2021-07-26
SI3324951T1 (sl) 2021-09-30
CA2990532A1 (en) 2017-01-26
US20200022926A1 (en) 2020-01-23
RS62142B1 (sr) 2021-08-31
WO2017013120A1 (en) 2017-01-26
AU2016296216A1 (en) 2017-12-14
HK1251176A1 (zh) 2019-01-25
DK3324951T3 (da) 2021-08-23
CN110075307A (zh) 2019-08-02
CO2018000236A2 (es) 2018-06-12
CA2990532C (en) 2020-07-14
EP3324951A1 (en) 2018-05-30
CN107921009B (zh) 2020-12-11
EP3120842A1 (en) 2017-01-25
RU2018106122A (ru) 2019-08-20
HRP20211319T1 (hr) 2021-11-26
RU2718908C2 (ru) 2020-04-15
JP6448847B2 (ja) 2019-01-09
JP2018522894A (ja) 2018-08-16
KR20180048577A (ko) 2018-05-10
KR20190025759A (ko) 2019-03-11
AU2016296216B2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
JP4965043B2 (ja) 抗癒着性炭水化物
AU2016212030B2 (en) Glycan therapeutics and related methods thereof
US11160766B2 (en) Peritoneal therapeutic fluid
US20250249025A1 (en) Drug delivery carrier utilizing property of d-allose being uptaken by cancer cell, drug delivery method, and composition for treating renal cell carcinoma
US20030130205A1 (en) Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use
HK40011489A (en) Peritoneal therapeutic fluid
HK1251176B (zh) 腹膜治疗液
RU2749443C2 (ru) Углеводные композиции для диализа
US11185514B2 (en) Aqueous solution comprising a polyphenol
JP5646164B2 (ja) 分岐キトサン誘導体
HK1254524B (en) Aqueous solution comprising a stilbenoid
US20220313828A1 (en) Use of low-molecular glycosidically bound terminal galactosides and fucosides for bonding to toxins that act as galectins in the treatment of intoxications, in particular ricin intoxications

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190304

Application number text: 1020187001830

Filing date: 20180119

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200721

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200810

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210317

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210614

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration